Impact of pharmaceutical validation on prescribing errors in a Neonatal Intensive Care Unit.
Not Applicable
Completed
- Conditions
- Prevention of medical errors in newbornsPregnancy and Childbirth
- Registration Number
- ISRCTN12370877
- Lead Sponsor
- Hospital Universitario 12 De Octubre
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 240
Inclusion Criteria
All patients born during the study period who were admitted to the NICU and stayed for at least 24 hours and with active pharmacological treatment
Exclusion Criteria
Patients admitted without pharmacological treatment or less than 24h.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage of prescription errors detected by a clinical pharmacist in e-prescribing measured at the end of the study
- Secondary Outcome Measures
Name Time Method Percentage of prescribing errors reaching the patient according to the nursing administration record measured at the end of the study
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie pharmaceutical validation in reducing neonatal prescribing errors?
How does pharmaceutical validation compare to standard-of-care practices in NICU error prevention?
Are there biomarkers that predict neonatal response to pharmaceutical validation strategies?
What adverse drug events are associated with NICU prescribing errors and how are they managed?
What technologies or systems are used in pharmaceutical validation for NICU drug safety?